

ESMO 2024

BARCELONE DU 13 AU 17 SEPTEMBRE 2024

I. Poster session

1. **143P - Efficacy of immunotherapy in gastro-intestinal (GI) tumors with mismatch repair deficient (MMRd) unusual phenotype**

Presentation Number

Speakers : **Emily Alouani** (Toulouse, Cedex 9, France)

Guillaume Roces (Toulouse, Cedex 9, France) David Tougeron (Poitiers, France, CEDEX) **Marion JaffreLOT** (Toulouse, France) Simon Pernot (33000, France) Thibault Mazard (Montpellier, Cedex 5, France) Vincent Hautefeuille (Amiens, France, CEDEX) Meher Ben Abdelghani (Strasbourg, France) Marie Duthelage (Rouen, France) Romain Cohen (Paris, France) Francesco Sciafani (Brussels, Belgium) Marie Muller (Nancy, France) Thomas Aparicio (Paris, France, CEDEX) Clelia Coutzac (Lyon, France) Antoine Hollebecque (Villejuif, Cedex, France) Marie Decraecker (Pessac, France) Pauline Parent (Lille, France) Julien Taieb (Paris, France) **Rosine Guimbaud** (Toulouse, France, CEDEX 3) **Janick Selves** (Toulouse, France)

2. **1366P - Natural Language Processing (NLP) as promising artificial intelligence (AI) tool to improve patients (pts) enrollment in clinical trials (CT): Analysis in real-world conditions on a lung cancer cohort**

Speakers : **Julien Mazieres** (Toulouse, France)

Julien Mazieres (Toulouse, France) Lorraine HOUVET (PARIS, France) **Siham Mallah** (Toulouse, France) **Audrey Rabeau** (Toulouse, France) **Laurence Bigay-Game** (Toulouse, France) **Robin Schwob** (Toulouse, France) **Jean-Marc Alliot** (Toulouse, France) Vincent Susplugas (PARIS, France) Vincent Domange (PARIS, France)

3. **1911P - Implementation of remote patient monitoring in thoracic oncology: A real-world experience from 489 pts across 41 centers in France**

Laurent Greillier (Marseille, France) Benjamin Besse (Villejuif, Cedex, France, CEDEX) Herve Pegliasco (Marseille, France) Simon Deshayes (Caen, France) Jean-Marc Vernejoux (QUINT-FONSEGRIVES, France) Dimitri Leite Ferreira (Caen, Cedex 9, France) Claire Tissot (Saint-Etienne, France) Benjamin Huret (Lille, France) Maximilien Autheman (Paris, France) Claudia Parisi (Villejuif, Cedex, France) Myriam Delaunay (Paris, France) **Julien Mazieres** (Toulouse, France)

4. **540P - Early treatment discontinuation (ETD) in dMMR/MSI-H metastatic colorectal cancer (mCRC) treated with immune checkpoint inhibitors (ICIs)**

Julien Taieb (Paris, France) Margherita Ambrosini (Milan, Italy) **Emily Alouani** (Toulouse, Cedex 9, France) Sara Lonardi (Padova, Italy) Frank A. Sinicrope (Rochester, United States of America, MN) Marie Decraecker (Pessac, France) Antoine Hollebecque (Villejuif, Cedex, France) Emilie Hafliger (Paris, France) Thibault Mazard (Montpellier, Cedex 5, France) Simon Pernot (33000, France) Pauline Parent (Lille, France) Maria Elena Elez Fernandez (Barcelona, Spain) Michael J. Overman (Houston, United States of America, TX) Priya Jayachandran (Los Angeles, United States of America) Vincenzo Nasca (Milan, Italy) Lisa Salvatore (Rome, Italy) **Rosine Guimbaud** (Toulouse, France, CEDEX 3) Chiara Cremolini (Pisa, Italy) David Tougeron (Poitiers, France, CEDEX) Filippo Pietrantonio (Milan, Italy)

5. 594P - Genetic and transcriptomic analyses of Early-Onset Colon Cancer (EOCC): A post-hoc analysis of 2973 patients (pts) from two adjuvant randomized trials

Annalice Gandini (Genova, Italy) Claire Gallois (Paris, France) H el ene Blons (Paris, France) Claire Mulot (Paris, France) Natacha Agueeff (Paris, France) Come Lepage (Dijon, France, Cedex) **Rosine Guimbaud** (Toulouse, France, CEDEX 3) Laurent Mineur (Avignon, France, CEDEX 2) Jerome Desrame (Lyon, France, CEDEX 8) Benoist Chibaudel (Levallois-Perret, France) Aur elien De Reynies (Paris, France) Thierry Andr e (Paris, France, CEDEX 12) Pierre Laurent-Puig (Paris, France) Julien Taieb (Paris, France)

6. 1260P - Efficacy and safety of sunvozertinib in prior platinum treated NSCLC patients with EGFR exon 20 insertion mutations: Primary analysis from the multinational WU-KONG1B pivotal study

Ludovic Doucet (Angers, France) Laurent Greillier (Marseille, France) David Planchard (Villejuif, Cedex, France) **Julien Mazieres** (Toulouse, France) Enriqueta Felip (Barcelona, Spain) Joaquim Bosch-Barrera (Girona, Spain) Manuel A. Cobo Dols (Malaga, Spain) Francois Ghiringhelli (Dijon, France) Alessandra Bearz (Aviano, Italy) Luis G. Paz-Ares (Madrid, Spain) Marcello Tiseo (Parma, Italy) Enric Carcereny (Badalona, Spain, Barcelona) Gerard Zalcman (Paris, France, CEDEX 18) Vincenzo P. Di Noia (Rome, Italy) Javier De Castro Carpe o (Madrid, Spain) Hector Jos e Soto Parra (Catania, Italy, (MI)) Jes s Corral Jaime (Sevilla, Spain) Li Zheng (Shanghai, China) James Chih-Hsin Yang (Taipei City, Taiwan) Pasi A. J anne (Boston, United States of America, MA)

7. 1307P - Clinical characteristics and therapeutic sequences of KRAS G12C advanced non-small cell lung cancer (aNSCLC) patients (pts) treated by sotorasib in the French post-marketing authorization early access (post-MA EA)

Jacques Cadranel (Paris, France) Hubert Curcio (Caen, Cedex 5, France) Youssef Oulkhair (Angers, Cedex 9, France) Sebastien Couraud (LYON, France, CEDEX) Romane Gille (Lyon, France) **Julien Mazieres** (Toulouse, France) Anne-C ecile M etivier (Suresnes, France) Nicolas Girard (Paris, France) Marie Wislez (Paris, France) Florian Guisier (Rouen, France) Hamadi Almotlak (Besancon, France, CEDEX) Xavier Quantin (Montpellier, Cedex 5, France) Claire Bardel (Pessac, France) Charles Naltet (Paris, France) Anne-Catherine Madroszyk Flandin (Marseille, Cedex 09, France, CEDEX 9) Benoit Roch (Montpellier, France, CEDEX 5) Laurent Greillier (Marseille, France) Charlotte Cl ement (Neuilly-sur-Seine, France) L ea De Gunten (Boulogne-Billancourt, France) Valerie Gounant (Paris, France, CEDEX 18)

8. 1380P - PK/PD analysis of pembrolizumab, nivolumab and atezolizumab in NSCLC patients: The PIONeer trial

Joseph Ciccolini (Marseille, France) Mourad Hamimed (Marseille, France) Sophie Marolleau (Marseille, Cedex 07, France) Carla Perez (Marseille, Cedex 07, France) Sebastien Benzekry (Le Chesnay, France) Maryannick Le Ray (Marseille, Cedex 07, France) Arnaud Boyer (Marseille, Cedex 08, France) Clarisse Audigier-Valette (Toulon, France) Stephanie Martinez (Aix-en-Provence, France) Herve Pegliasco (Marseille, France) Patrice Ray (Nimes, Cedex 9, France, CEDEX 9) Lionel Falchero (Villefranche-Sur-Saone, France) Antoine Serre (Nimes, France, Cedex 2) Nicolas Cloarec (Avignon, Cedex 9, France) Louisiane Lebas (Toulouse, France) Stephane Hominal (Epagny Metz Tessy, France, CEDEX) **Julien Mazieres** (Toulouse, France) Maurice P erol (Lyon, France, CEDEX) Laurent Greillier (Marseille, France) Fabrice Barlesi (Villejuif, France, CEDEX 20)

9. 1324P - Durvalumab in treatment-naive, stage IV non-small cell lung cancer (NSCLC) patients (pts), with ECOG performance status (PS) 2-3 and high PD-L1 tumour expression: Results of IFCT-1802 SAVIMMUNE phase II trial

Valerie Gounant (Paris, France, CEDEX 18) Laurent Greillier (Marseille, France) Céline Mascaux (Strasbourg, France) François Pinquie (Le Mans, France) Delphine Carmier (Tours, cedex 9, France) Lionel Moreau (Colmar, France, CEDEX) Benoit Roch (Montpellier, France, CEDEX 5) Didier Debievre (Mulhouse, France) Xavier Dhalluin (Lille, France) Etienne Giroux-Leprieur (Boulogne-Billancourt, France) Elodie Berton (La Tronche, France) **Audrey Rabeau** (Toulouse, France) Judith Raimbourg (Saint-Herblain, France, FR) Adrien Dixmier (Orleans, France) Charles Naltet (Paris, France) Antoine Khalil (Paris, France) Lynn Ezzeddine (Paris, France) Alexandra Langlais (Paris, France) Franck Morin (Paris, France) Michael Duruisseaux (Lyon, France)

10. 1286P - Explore-ALK (GFPC 03-2019): A real-world prospective, multicenter study of advanced ALK rearranged non-small cell lung cancer patients

Chantal Decroisette (Lyon, France, CEDEX) Renaud Descourt (Brest, France) Gaele Rousseau Bussac (Creteil, France) Aurélie Swalduz (Lyon, France) Olivier Bylicki (Toulon, Cedex 9, France) **Laurence Bigay-Game** (Toulouse, France) Helene Doubre (Suresnes, France) Alexis B. Cortot (Lille, France) Stephane Hominal (Epagny Metz Tussy, France, CEDEX) Lionel Falchero (Villefranche-Sur-Saone, France) Florian Guisier (Rouen, France) Mael Domblides (quimper, France) Regine Lamy (Lorient, France) Julian Pinsolle (Grenoble, France) Charles Ricordel (Rennes, France) Diane Moreau (Saint-Pierre, Reunion Islands) Stephanie Martinez (Aix-en-Provence, France) Grégoire Justeau (Angers, Cedex 9, France) Christos Chouaid (Créteil, France) Laurent Greillier (Marseille, France)

11. 1292P - A national real-world analysis of ROS1+ metastatic non-small cell lung cancer patients management (explore ALK, cohort 2, GFPC 03-2019)

Gaele Rousseau Bussac (Creteil, France) Florian Guisier (Rouen, France) Remi Veillon (, France) Helene Doubre (Suresnes, France) Alexis B. Cortot (Lille, France) Lionel Moreau (Colmar, France, CEDEX) Thomas Pierret (Bron, France) Lionel Falchero (Villefranche-Sur-Saone, France) Grégoire Justeau (Angers, Cedex 9, France) Charles Ricordel (Rennes, France) Hugues Morel (Orleans, France) Karim Amrane (Brest, France) **Laurence Bigay-Game** (Toulouse, France) Stephane Hominal (Epagny Metz Tussy, France, CEDEX) Stephanie Martinez (Aix-en-Provence, France) Patrick Aldo Renault (Pau, France) Diane Moreau (Saint-Pierre, Reunion Islands) Marie Marcq (La Roche-sur-Yon, France) Renaud Descourt (Brest, France) Laurent Greillier (Marseille, France)

II. Presidential symposium

1. LBA2 - POD1UM-303/InterAACT 2: Phase III study of retifanlimab with carboplatin- paclitaxel (c-p) in patients (Pts) with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC) not previously treated with systemic chemotherapy (Chemo)

S. Rao, E. Samalin-Scalzi, L. Evesque, M. Ben Abdelghani, F. Morano, A. Roy, L. Dahan, S. Tamberi, A. Dhadda, M. Saunders, N. Casanova, **R. Guimbaud**, A. Lievre, J. Maurel, M. Fakih, P. Zhang, J. Harrison, M. Jones, J.-P. Spano, P. Rochefort.

2. LBA8 - Precision immuno-oncology for advanced non-small cell lung cancer (NSCLC) patients with PD-(L)1 inhibitors resistance (PIONeer): A phase Ib/IIa clinical trial targeting identified resistance pathways

Pascale Tomasini, Claire Cropet, Arnaud Jeanson, Maurice Pérol, **Julien Mazières**, Catherine Fontaine, **Audrey Rabeau**, Marie Meurer, Laurent Greillier, Maryannick Le Ray, Lilian Laborde,

Anita Cohen, Virginie Martin, Marie Roumieux, Florence Monville, Eric Vivier,
David Pérol, Sylvie Chabaud, Fabrice Barlesi.

III. Mini Oral session

1. **1259MO - Encorafenib plus binimetinib in patients (pts) with previously untreated BRAF V600E-mutant advanced non-small cell lung cancer (NSCLC): An open-label, multicenter phase II trial (IFCT-1904 ENCO-BRAF)**

Deuxième auteur Julien Mazières

2. **LBA85 - TAR-200 +/- cetrelimab (CET) and CET alone in patients (pts) with bacillus Calmette-Guérin-unresponsive (BCG UR) high-risk non-muscle-invasive bladder cancer (HR NMIBC): Updated results from SunRISe-1 (SR-1)**

Mathieu Roumiguié

IV. Proffered Paper sesión

1. **1253O - Phase I/II ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumours.**

Julien Mazières

2. **LBA83 - PECATI: A phase II trial to evaluate the efficacy and safety of lenvatinib in combination with pembrolizumab in pretreated advanced B3-thymoma and thymic carcinoma**

Laurence Bigay-Game